DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy

Abstract

Background Chemoresistance often develops in esophageal squamous cell carcinoma (ESCC), leading to poor prognosis. HOX genes play a crucial role in embryonic development and cell differentiation. Studies have recently linked HOX with chemoresistance, thus we explored whether HOXA13 is involved in ESCC chemoresistance. Methods One hundred thirty‐one ESCC patients who received neoadjuvant chemotherapy were enrolled. HOXA13 expression was examined by immunohistochemistry. RNA interference was used to knock down the HOXA13 expression in KYSE70 and transfected HOXA13 plasmid to overexpress HOXA13 in KYSE510 cells. We examined half‐maximal inhibitory concentration of cisplatin, apoptosis, and epithelial‐to‐mesenchymal transition (EMT) in ESCC cell lines with different HOXA13 expression levels by cell counting kit‐8, flow cytometry, and transwell analysis. Results The median survival of patients with high HOXA13 expression was significantly shorter than those with low expression ( P  = 0.027). HOXA13 was associated with worse tumor regression grade ( P  = 0.009). Low HOXA13 expressed cells decreased the half‐maximal inhibitory concentration of cisplatin ( P  < 0.05), increased cisplatin‐induced apoptosis ( P  < 0.05), and decreased EMT ( P  < 0.05) compared with high HOXA13 expressed cells. In low HOXA13 expressed cells, cleaved caspase‐3 and cleaved PARP expression induced by cisplatin increased, while expression of E‐cadherin and Snail protein, markersmore » of EMT, was upregulated and downregulated, respectively. EMT decreased in low HOXA13 expressed cells. Conclusion High HOXA13 expression was associated with inferior tumor regression grade and poor overall survival in ESCC patients treated with neoadjuvant chemotherapy. HOXA13 increased cisplatin‐resistance and promoted EMT in ESCC cells.« less

Authors:
 [1];  [1];  [2];  [1];  [1];  [1];  [1];  [1]; ORCiD logo [1]
  1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery I Peking University Cancer Hospital &, Institute Beijing China
  2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology Peking University Cancer Hospital &, Institute Beijing China
Publication Date:
Sponsoring Org.:
USDOE
OSTI Identifier:
1437069
Alternate Identifier(s):
OSTI ID: 1458578
Resource Type:
Published Article
Journal Name:
Thoracic Cancer
Additional Journal Information:
Journal Name: Thoracic Cancer Journal Volume: 9 Journal Issue: 7; Journal ID: ISSN 1759-7706
Publisher:
Wiley-Blackwell
Country of Publication:
Australia
Language:
English

Citation Formats

Shi, Qi, Shen, Luyan, Dong, Bin, Fu, Hao, Kang, Xiaozheng, Dai, Liang, Yang, Yongbo, Yan, Wanpu, and Chen, Ke‐Neng. Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy. Australia: N. p., 2018. Web. doi:10.1111/1759-7714.12758.
Shi, Qi, Shen, Luyan, Dong, Bin, Fu, Hao, Kang, Xiaozheng, Dai, Liang, Yang, Yongbo, Yan, Wanpu, & Chen, Ke‐Neng. Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy. Australia. https://doi.org/10.1111/1759-7714.12758
Shi, Qi, Shen, Luyan, Dong, Bin, Fu, Hao, Kang, Xiaozheng, Dai, Liang, Yang, Yongbo, Yan, Wanpu, and Chen, Ke‐Neng. Mon . "Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy". Australia. https://doi.org/10.1111/1759-7714.12758.
@article{osti_1437069,
title = {Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy},
author = {Shi, Qi and Shen, Luyan and Dong, Bin and Fu, Hao and Kang, Xiaozheng and Dai, Liang and Yang, Yongbo and Yan, Wanpu and Chen, Ke‐Neng},
abstractNote = {Background Chemoresistance often develops in esophageal squamous cell carcinoma (ESCC), leading to poor prognosis. HOX genes play a crucial role in embryonic development and cell differentiation. Studies have recently linked HOX with chemoresistance, thus we explored whether HOXA13 is involved in ESCC chemoresistance. Methods One hundred thirty‐one ESCC patients who received neoadjuvant chemotherapy were enrolled. HOXA13 expression was examined by immunohistochemistry. RNA interference was used to knock down the HOXA13 expression in KYSE70 and transfected HOXA13 plasmid to overexpress HOXA13 in KYSE510 cells. We examined half‐maximal inhibitory concentration of cisplatin, apoptosis, and epithelial‐to‐mesenchymal transition (EMT) in ESCC cell lines with different HOXA13 expression levels by cell counting kit‐8, flow cytometry, and transwell analysis. Results The median survival of patients with high HOXA13 expression was significantly shorter than those with low expression ( P  = 0.027). HOXA13 was associated with worse tumor regression grade ( P  = 0.009). Low HOXA13 expressed cells decreased the half‐maximal inhibitory concentration of cisplatin ( P  < 0.05), increased cisplatin‐induced apoptosis ( P  < 0.05), and decreased EMT ( P  < 0.05) compared with high HOXA13 expressed cells. In low HOXA13 expressed cells, cleaved caspase‐3 and cleaved PARP expression induced by cisplatin increased, while expression of E‐cadherin and Snail protein, markers of EMT, was upregulated and downregulated, respectively. EMT decreased in low HOXA13 expressed cells. Conclusion High HOXA13 expression was associated with inferior tumor regression grade and poor overall survival in ESCC patients treated with neoadjuvant chemotherapy. HOXA13 increased cisplatin‐resistance and promoted EMT in ESCC cells.},
doi = {10.1111/1759-7714.12758},
journal = {Thoracic Cancer},
number = 7,
volume = 9,
place = {Australia},
year = {Mon May 14 00:00:00 EDT 2018},
month = {Mon May 14 00:00:00 EDT 2018}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
https://doi.org/10.1111/1759-7714.12758

Citation Metrics:
Cited by: 16 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53-Mediated Apoptosis and Acquiring a Stem-Like Phenotype in Ovarian Cancer Cells
journal, September 2009

  • Kurrey, Nawneet K.; Jalgaonkar, Swati P.; Joglekar, Alok V.
  • Stem Cells, Vol. 27, Issue 9
  • DOI: 10.1002/stem.154

Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
journal, August 2010

  • Tang, Chi-Hui; Parham, Christi; Shocron, Ellyn
  • Cancer Chemotherapy and Pharmacology, Vol. 67, Issue 6
  • DOI: 10.1007/s00280-010-1435-5

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
journal, November 2015

  • Zheng, Xiaofeng; Carstens, Julienne L.; Kim, Jiha
  • Nature, Vol. 527, Issue 7579
  • DOI: 10.1038/nature16064

Exploration of target genes of HOXA13 in esophageal squamous cell carcinoma cell line
journal, December 2011


Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling
journal, March 2017


Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation
journal, February 2005

  • Chirieac, Lucian R.; Swisher, Stephen G.; Ajani, Jaffer A.
  • Cancer, Vol. 103, Issue 7
  • DOI: 10.1002/cncr.20916

HOXA13 Promotes Cancer Cell Growth and Predicts Poor Survival of Patients with Esophageal Squamous Cell Carcinoma
journal, June 2009


HOXA13 is associated with unfavorable survival and acts as a novel oncogene in prostate carcinoma
journal, July 2017


Expression of Snail in Pancreatic Cancer Promotes Metastasis and Chemoresistance
journal, August 2007


Increased HOXC6 expression predicts chemotherapy sensitivity in patients with esophageal squamous cell carcinoma
journal, August 2017

  • Shen, Lu-Yan; Fan, Meng-Ying; Dong, Bin
  • Oncology Letters, Vol. 14, Issue 4
  • DOI: 10.3892/ol.2017.6772

Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer
journal, January 2017


Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
journal, March 2007


Knockdown of Homeobox B5 (HOXB5) Inhibits Cell Proliferation, Migration, and Invasion in Non-Small Cell Lung Cancer Cells Through Inactivation of the Wnt/β-Catenin Pathway
journal, January 2018

  • Zhang, Bin; Li, Na; Zhang, Hao
  • Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Vol. 26, Issue 1
  • DOI: 10.3727/096504017X14900530835262

Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance
journal, October 2011

  • Chao, Yvonne; Wu, Qian; Shepard, Christopher
  • Clinical & Experimental Metastasis, Vol. 29, Issue 1
  • DOI: 10.1007/s10585-011-9427-3

Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries
journal, January 2015


Cancer incidence and mortality in China, 2013
journal, August 2017


Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100
journal, May 2014


HOXB5 Promotes the Proliferation and Invasion of Breast Cancer Cells
journal, January 2015

  • Lee, Ji-Yeon; Hur, Ho; Yun, Hyo Jung
  • International Journal of Biological Sciences, Vol. 11, Issue 6
  • DOI: 10.7150/ijbs.11431

Knockdown of homeobox A5 by small hairpin RNA inhibits proliferation and enhances cytarabine chemosensitivity of acute myeloid leukemia cells
journal, September 2015

  • Li, Na; Jia, Xiuhong; Wang, Jianyong
  • Molecular Medicine Reports, Vol. 12, Issue 5
  • DOI: 10.3892/mmr.2015.4331

E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells
journal, February 2012

  • Kim, W. D.; Kim, Y. W.; Cho, I. J.
  • Journal of Cell Science, Vol. 125, Issue 5
  • DOI: 10.1242/jcs.095422

High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models
journal, October 2017

  • Quagliata, Luca; Quintavalle, Cristina; Lanzafame, Manuela
  • Laboratory Investigation, Vol. 98, Issue 1
  • DOI: 10.1038/labinvest.2017.107

Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction
journal, September 2014

  • Davies, Andrew R.; Gossage, James A.; Zylstra, Janine
  • Journal of Clinical Oncology, Vol. 32, Issue 27
  • DOI: 10.1200/JCO.2014.55.9070

Multimodality Approaches for the Curative Treatment of Esophageal Cancer
journal, February 2015

  • Jang, Raymond; Darling, Gail; Wong, Rebecca K. S.
  • Journal of the National Comprehensive Cancer Network, Vol. 13, Issue 2
  • DOI: 10.6004/jnccn.2015.0029

Overexpression of HOXA13 as a Potential Marker for Diagnosis and Poor Prognosis of Hepatocellular Carcinoma
journal, January 2014

  • Pan, Ting-Ting; Jia, Wei-Dong; Yao, Qi-Yang
  • The Tohoku Journal of Experimental Medicine, Vol. 234, Issue 3
  • DOI: 10.1620/tjem.234.209

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
journal, May 2012

  • van Hagen, P.; Hulshof, M. C. C. M.; van Lanschot, J. J. B.
  • New England Journal of Medicine, Vol. 366, Issue 22
  • DOI: 10.1056/NEJMoa1112088